Company Biofrontera AG

B8F

DE0006046113

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Xetra Other stock markets 11:36:13 2023-12-04 am EST			5-day change	1st Jan Change
0.47 ^EUR	+4.21%		-4.47%	-69.18%

Nov. 28	Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
Nov. 09	Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	MT

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

Number of employees : 92

EUR in Million	2021	Weight	2022	Weight	Delta
Pharmaceutical and Medical Products 100.0 %	29	100.0 %	26	100.0 %	-10.59%

EUR in Million	2021	Weight	2022	Weight	Delta
United States 66.6 %	20	70.3 %	17	66.6 %	-15.19%
Germany 18.5 %	5	18.3 %	5	18.5 %	-9.50%
Europe 13.6 %	3	11.4 %	3	13.6 %	+6.94%
Other Regions 1.3 %	-	-	0	1.3 %	-

Managers	Title	Age	Since
María del Pilar de la Huerta Martínez DFI	Director of Finance/CFO	54	2022
Anke zur Muehlen IRO	Public Communications Contact	-	-

Members of the board	Title	Age	Since
Wilhelm Konrad Zours CHM	Chairman	62	2021
Karlheinz Schmelig BRD	Director/Board Member	-	2021
Heikki Lanckriet BRD	Director/Board Member	46	2021
Helge Lubenow BRD	Director/Board Member	55	2021
Jörgen Thielmann BRD	Director/Board Member	-	2021

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	63,807,058	28,464,417 ( 44.61 %)	0	44.61 %

Name	Equities	%	Valuation
Maruho Co., Ltd. 21.00 %	13,399,965	21.00 %	8 M €
BIOFRONTERA INC. 9.968 %	6,360,146	9.968 %	4 M €
Arvernus Capital AG 0.0125 %	7,992	0.0125 %	4 646 €
Baader Bank AG (Investment Management) 0.0109 %	6,929	0.0109 %	4 028 €

Name	Equities	%	Valuation
BIOFRONTERA INC. 29.25%	400,000	29.25%	1,880,000 $

Biofrontera AG

Hemmelrather Weg 201

51377, Leverkusen

http://biofrontera.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
BIOFRONTERA AG	-69.18%	31 M $
ELI LILLY AND COMPANY	+60.09%	525 B $
NOVO NORDISK A/S	+47.59%	454 B $
JOHNSON & JOHNSON	-10.06%	381 B $
MERCK & CO., INC.	-5.31%	262 B $
ABBVIE INC.	-10.80%	253 B $
ROCHE HOLDING AG	-15.22%	221 B $
NOVARTIS AG	+3.05%	202 B $
ASTRAZENECA PLC	-8.49%	200 B $
PFIZER, INC.	-42.86%	163 B $